Emerald Mutual Fund Advisers Trust Lowers Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Emerald Mutual Fund Advisers Trust lessened its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 15.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 549,688 shares of the specialty pharmaceutical company's stock after selling 101,292 shares during the quarter. Emerald Mutual Fund Advisers Trust owned approximately 1.11% of KalVista Pharmaceuticals worth $4,656,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Aquatic Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $44,000. Tower Research Capital LLC TRC increased its stake in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after buying an additional 5,502 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares during the last quarter. Martin Worley Group purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par purchased 73,649 shares of the business's stock in a transaction on Friday, February 7th. The shares were bought at an average price of $9.29 per share, with a total value of $684,199.21. Following the completion of the transaction, the insider now directly owns 5,086,445 shares in the company, valued at approximately $47,253,074.05. This represents a 1.47 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares of the company's stock, valued at approximately $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 217,348 shares of company stock worth $2,014,773 and have sold 17,292 shares worth $184,625. 10.50% of the stock is owned by insiders.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded down $0.05 during trading hours on Friday, reaching $13.55. The stock had a trading volume of 520,715 shares, compared to its average volume of 410,013. The stock has a market capitalization of $673.65 million, a price-to-earnings ratio of -3.72 and a beta of 0.05. The firm's 50 day moving average is $11.90 and its 200-day moving average is $10.40. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $15.50.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KALV. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Finally, TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of "Buy" and an average target price of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).